Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Appendicitis-II: Diagnostic Studies and Management01:29

Appendicitis-II: Diagnostic Studies and Management

562
Diagnosing and managing appendicitis requires a structured and comprehensive approach that spans from initial assessment to postoperative care. Here is an overview of the process:
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
562
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

2.4K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.4K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

217
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
217
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

321
Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
321
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

522
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
522

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation.

HemaSphere·2026
Same author

Cancer clinical trial recruitment for patients from rural areas: a scoping review.

International journal for equity in health·2026
Same author

Living with chronic lymphocytic leukaemia: A qualitative evidence synthesis of patient, caregiver and practitioner perspectives.

European journal of oncology nursing : the official journal of European Oncology Nursing Society·2026
Same author

Baricitinib and ruxolitinib use through the UK HLH Network.

The Lancet. Rheumatology·2026
Same author

Belantamab mafodotin-associated keratopathy: Clinical outcomes and management from two UK tertiary centres.

British journal of haematology·2026
Same author

Sociodemographic and clinical determinants of general practice consultation frequency among regular patients in Australia: a national study.

BJGP open·2026

Related Experiment Video

Updated: Jan 29, 2026

Author Spotlight: Engineering Molecular Tools for Disease Detection and Imaging
04:33

Author Spotlight: Engineering Molecular Tools for Disease Detection and Imaging

Published on: December 8, 2023

1.4K

Relevance of TP53 for CLL diagnostics.

Mark A Catherwood1, David Gonzalez2, David Donaldson3

  • 1Haematology Department, Belfast Health and Social Care Trust, Belfast, UK mark.catherwood@belfasttrust.hscni.net.

Journal of Clinical Pathology
|February 4, 2019
PubMed
Summary

TP53 gene mutations are critical for chronic lymphocytic leukemia (CLL) prognosis and treatment. Current detection methods miss some mutations, potentially impacting patient care. Next-generation sequencing offers improved TP53 mutation detection in CLL.

Keywords:
Deletion 17pchronic lymphocytic leukaemianext generation sequencingp53prognosis

More Related Videos

Microfluidic Applications for Disposable Diagnostics
10:21

Microfluidic Applications for Disposable Diagnostics

Published on: February 3, 2008

9.3K
A Model to Simulate Clinically Relevant Hypoxia in Humans
09:54

A Model to Simulate Clinically Relevant Hypoxia in Humans

Published on: December 22, 2016

9.4K

Related Experiment Videos

Last Updated: Jan 29, 2026

Author Spotlight: Engineering Molecular Tools for Disease Detection and Imaging
04:33

Author Spotlight: Engineering Molecular Tools for Disease Detection and Imaging

Published on: December 8, 2023

1.4K
Microfluidic Applications for Disposable Diagnostics
10:21

Microfluidic Applications for Disposable Diagnostics

Published on: February 3, 2008

9.3K
A Model to Simulate Clinically Relevant Hypoxia in Humans
09:54

A Model to Simulate Clinically Relevant Hypoxia in Humans

Published on: December 22, 2016

9.4K

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • TP53 gene disruption is a key prognostic marker in chronic lymphocytic leukemia (CLL).
  • Accurate TP53 status assessment is crucial for guiding CLL treatment decisions.
  • Current methods for detecting TP53 alterations have limitations in sensitivity and scope.

Purpose of the Study:

  • To review the structure, function, and regulation of the TP53 protein.
  • To discuss TP53 mutations in cancer and specifically in CLL.
  • To highlight the clinical relevance of TP53 disruption in CLL and evaluate current detection methods.

Main Methods:

  • Literature review focusing on TP53 gene, its mutations, and detection techniques in CLL.
  • Description of fluorescence in situ hybridization (FISH) for del(17p) and Sanger sequencing.
  • Introduction to next-generation sequencing (NGS) as an advanced screening method.

Main Results:

  • TP53 mutations are prevalent and significantly impact CLL patient outcomes.
  • Existing screening methods may fail to detect diagnostically relevant or low-level TP53 mutations.
  • Next-generation sequencing offers enhanced sensitivity and comprehensive TP53 mutation profiling.

Conclusions:

  • Improved TP53 mutation detection is essential for accurate prognostication and personalized treatment in CLL.
  • Next-generation sequencing represents a significant advancement over current methods for TP53 analysis in CLL.
  • Addressing the limitations of current screening methods can lead to more effective management of CLL patients with TP53 alterations.